Pub Date : 2023-05-22DOI: 10.17650/2782-3202-2023-3-2-40-46
P. A. Zeynalova, G. Allakhverdieva, Yu. E. Ryabukhina, F. М. Abbasbeyli, A. Batsev, O. L. Timofeeva, A. G. Zhukov, T. Valiev
During long-term autoimmune processes, most commonly in patients with Sjogren’s disease (SD), lymphoproliferative disorders (LPD) can develop. The risk of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) with involvement of parotid salivary glands is increased 1,000-fold compared to other immunomorphological variants. Some studies show that the main factors predisposing patients with SD to LPD are long-term enlargement of parotid salivary glands, generalized lymphadenopathy, cryoglobulinemic purpura. Application of an integrative approach to LDP diagnosis in patients with SD, identification of high-risk group for this malignant neoplasm promote its early detection.A clinical observation of a female patients with long-term SD which was diagnosed along with MALT lymphoma using an integrative approach to diagnosis of both diseases is presented.
{"title":"Integrative approach to diagnosis of lymphoproliferative disease during long-term Sjogren’s disease. Clinical observation","authors":"P. A. Zeynalova, G. Allakhverdieva, Yu. E. Ryabukhina, F. М. Abbasbeyli, A. Batsev, O. L. Timofeeva, A. G. Zhukov, T. Valiev","doi":"10.17650/2782-3202-2023-3-2-40-46","DOIUrl":"https://doi.org/10.17650/2782-3202-2023-3-2-40-46","url":null,"abstract":"During long-term autoimmune processes, most commonly in patients with Sjogren’s disease (SD), lymphoproliferative disorders (LPD) can develop. The risk of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) with involvement of parotid salivary glands is increased 1,000-fold compared to other immunomorphological variants. Some studies show that the main factors predisposing patients with SD to LPD are long-term enlargement of parotid salivary glands, generalized lymphadenopathy, cryoglobulinemic purpura. Application of an integrative approach to LDP diagnosis in patients with SD, identification of high-risk group for this malignant neoplasm promote its early detection.A clinical observation of a female patients with long-term SD which was diagnosed along with MALT lymphoma using an integrative approach to diagnosis of both diseases is presented.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115949297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-22DOI: 10.17650/2782-3202-2023-3-2-35-39
T. I. Kopaliani, A. A. Akhobekov, Z. M. Cheishvili, A. M. Grigoryan, B. G. Pkheshkhova, A. Mudunov
{"title":"Clinical case of surgical treatment of a patient with multivessel coronary artery disease and abdominal aortic aneurysm in combination with malignant tumor of the larynx","authors":"T. I. Kopaliani, A. A. Akhobekov, Z. M. Cheishvili, A. M. Grigoryan, B. G. Pkheshkhova, A. Mudunov","doi":"10.17650/2782-3202-2023-3-2-35-39","DOIUrl":"https://doi.org/10.17650/2782-3202-2023-3-2-35-39","url":null,"abstract":"","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122290039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-22DOI: 10.17650/2782-3202-2023-3-2-47-55
P. A. Zeynalova, Yu. E. Ryabukhina, F. М. Abbasbeyli, O. L. Timofeeva, G. Allakhverdieva, D. Abramov, T. Valiev
In the presented observation, a female patient with diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma (advanced stages) received R-ABVD regimen therapy. Return of clinical symptoms observed at the onset of the disease, as well as renewed growth of the lymph nodes after 4th therapy cycle showed refractory disease. Considering the results of earlier studies, generally showing high effectiveness of primary treatment of patients with nodular lymphocyte-predominant Hodgkin lymphoma, reevaluation of immunomorphological type of lymphoproliferative disease was performed. After change of diagnosis to grade 3A follicular lymphoma, therapy was changed to obinutuzumab in combination with bendamustine leading to fast positive antitumor effect.
{"title":"Integrative approach to diagnosis and subsequent successful therapy of refractory follicular lymphoma using obinutuzumab in combination with bendamustine. Clinical observation","authors":"P. A. Zeynalova, Yu. E. Ryabukhina, F. М. Abbasbeyli, O. L. Timofeeva, G. Allakhverdieva, D. Abramov, T. Valiev","doi":"10.17650/2782-3202-2023-3-2-47-55","DOIUrl":"https://doi.org/10.17650/2782-3202-2023-3-2-47-55","url":null,"abstract":"In the presented observation, a female patient with diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma (advanced stages) received R-ABVD regimen therapy. Return of clinical symptoms observed at the onset of the disease, as well as renewed growth of the lymph nodes after 4th therapy cycle showed refractory disease. Considering the results of earlier studies, generally showing high effectiveness of primary treatment of patients with nodular lymphocyte-predominant Hodgkin lymphoma, reevaluation of immunomorphological type of lymphoproliferative disease was performed. After change of diagnosis to grade 3A follicular lymphoma, therapy was changed to obinutuzumab in combination with bendamustine leading to fast positive antitumor effect.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125090588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-20DOI: 10.17650/2782-3202-2023-3-2-20-26
I. N. Iurichev, V. Vereshchak, V. E. Gruzdev, M. A. Anisimov, A. A. Filatov
Endoscopic trachea stenting is a pressing issue in modern endoscopy. This method is applied in various diseases including benign stenoses associated with complications after long-term mechanical ventilation, malignant stenoses (oncological diseases of the trachea itself, compression from outside by esophageal or mediastinal tumors), post-injury stenoses and developmental defects.Currently, a certain contingent of patients exists for whom trachea prosthesis and its bifurcation remain the only possible option for stepwise or final treatment. If the lower third of the trachea, bifurcation zone or the main bronchi are affected, the optimal technique is stenting with Y-shaped stents which provide maximal patency of the airways.
{"title":"First experience of trachea stenting using a Y-shaped stent. Clinical observation","authors":"I. N. Iurichev, V. Vereshchak, V. E. Gruzdev, M. A. Anisimov, A. A. Filatov","doi":"10.17650/2782-3202-2023-3-2-20-26","DOIUrl":"https://doi.org/10.17650/2782-3202-2023-3-2-20-26","url":null,"abstract":"Endoscopic trachea stenting is a pressing issue in modern endoscopy. This method is applied in various diseases including benign stenoses associated with complications after long-term mechanical ventilation, malignant stenoses (oncological diseases of the trachea itself, compression from outside by esophageal or mediastinal tumors), post-injury stenoses and developmental defects.Currently, a certain contingent of patients exists for whom trachea prosthesis and its bifurcation remain the only possible option for stepwise or final treatment. If the lower third of the trachea, bifurcation zone or the main bronchi are affected, the optimal technique is stenting with Y-shaped stents which provide maximal patency of the airways.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"36 7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129169760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-20DOI: 10.17650/2782-3202-2023-3-2-27-34
Yu. E. Ryabukhina, P. A. Zeynalova, O. L. Timofeeva, F. М. Abbasbeyli, V. E. Gruzdev, A. O. Akhov, A. G. Zhukov, T. Valiev
Chronic pain syndrome developing in patients with oncological diseases significantly decreases their quality of life which makes effective integrative analgetic therapy a pressing issue. Currently, drugs of various pharmaceutical groups are used for pain management and administered subsequentially in accordance with the pain intensity visual analogue scale. For moderate and severe pain syndrome, opioid analgesics are used which have side effects limiting their use in some cases. Trials showed that new highly specific μ1-opioid receptor agonist tafalgin is characterized by high bioavailability, fast absorption, biotransformation, absence of accumulation which makes its safety profile favorable. Pronounced analgesic effect of tafalgin, as well as ease of administration and absence of significant adverse events, allow to significantly improve the quality of life of patients with chronic pain syndrome.
{"title":"Use of μ1-opioid receptor agonist tafalgin in integrative therapy of chronic pain syndrome in progressive multiple myeloma. Clinical observation","authors":"Yu. E. Ryabukhina, P. A. Zeynalova, O. L. Timofeeva, F. М. Abbasbeyli, V. E. Gruzdev, A. O. Akhov, A. G. Zhukov, T. Valiev","doi":"10.17650/2782-3202-2023-3-2-27-34","DOIUrl":"https://doi.org/10.17650/2782-3202-2023-3-2-27-34","url":null,"abstract":"Chronic pain syndrome developing in patients with oncological diseases significantly decreases their quality of life which makes effective integrative analgetic therapy a pressing issue. Currently, drugs of various pharmaceutical groups are used for pain management and administered subsequentially in accordance with the pain intensity visual analogue scale. For moderate and severe pain syndrome, opioid analgesics are used which have side effects limiting their use in some cases. Trials showed that new highly specific μ1-opioid receptor agonist tafalgin is characterized by high bioavailability, fast absorption, biotransformation, absence of accumulation which makes its safety profile favorable. Pronounced analgesic effect of tafalgin, as well as ease of administration and absence of significant adverse events, allow to significantly improve the quality of life of patients with chronic pain syndrome.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130114388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-20DOI: 10.17650/2782-3202-2023-3-2-16-19
N. M. Kutakov, D. Chekini
Currently, treatment of patients with early primary operable BRCA mutation-associated breast cancer requires integrative approach. A mutation in BRCA1/2 genes is a prognostically unfavorable factor increasing the risk of cancer of the contralateral breast, as well as ovaries, pancreas, fallopian tubes, and primary peritoneal cancer. In this clinical observation, an integrative multidisciplinary approach to treatment of a young patient with luminal B breast cancer is described which allowed to preserve the patient’s fertility and achieve pregnancy using assisted reproductive technologies.High effectiveness of the chosen treatment tactics in the framework of integrative approach in a specialized medical facility with experience in treatment of oncological diseases and preservation of reproductive function confirmed by clinical data and results of laboratory and instrumental exams is demonstrated.
{"title":"Perspectives and possibilities of preserving reproductive function in patients receiving antitumor treatment. Clinical observation","authors":"N. M. Kutakov, D. Chekini","doi":"10.17650/2782-3202-2023-3-2-16-19","DOIUrl":"https://doi.org/10.17650/2782-3202-2023-3-2-16-19","url":null,"abstract":"Currently, treatment of patients with early primary operable BRCA mutation-associated breast cancer requires integrative approach. A mutation in BRCA1/2 genes is a prognostically unfavorable factor increasing the risk of cancer of the contralateral breast, as well as ovaries, pancreas, fallopian tubes, and primary peritoneal cancer. In this clinical observation, an integrative multidisciplinary approach to treatment of a young patient with luminal B breast cancer is described which allowed to preserve the patient’s fertility and achieve pregnancy using assisted reproductive technologies.High effectiveness of the chosen treatment tactics in the framework of integrative approach in a specialized medical facility with experience in treatment of oncological diseases and preservation of reproductive function confirmed by clinical data and results of laboratory and instrumental exams is demonstrated.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"122 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134388262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-15DOI: 10.17650/2782-3202-2023-3-1-22-29
A. Rasulov, Z. Rasulov, J. Madyarov, A. E. Kulikov, Sh. A. Alishikhov, Yu. E. Lviv, R. A. Rasulov
Resection of “difficult” polyps is associated with high risks of intra- and postoperative complications. About 10 % of polyps are not amenable to endoscopic resection due to technical difficulties. Routinely, for the treatment of big size laterally spread tumors and early tumor of bowel segmental resections is used, which had a significantly higher risks of postoperative complications development. Hybrid laparoendoscopic surgery included a combination of laparoscopic and endoscopic technologies becomes a great opportunity to local bowel resection. This surgical procedure is accompanied by a minimal risk frequency of postoperative complications and the length of stay. In the two clinical cases we demonstrate techniques of hybrid laparoendoscopic surgery for “difficult” endoscopically unresectable polyps of the colon.
{"title":"Hybrid laparoendoscopic technologies in treatment of large colon polyps","authors":"A. Rasulov, Z. Rasulov, J. Madyarov, A. E. Kulikov, Sh. A. Alishikhov, Yu. E. Lviv, R. A. Rasulov","doi":"10.17650/2782-3202-2023-3-1-22-29","DOIUrl":"https://doi.org/10.17650/2782-3202-2023-3-1-22-29","url":null,"abstract":"Resection of “difficult” polyps is associated with high risks of intra- and postoperative complications. About 10 % of polyps are not amenable to endoscopic resection due to technical difficulties. Routinely, for the treatment of big size laterally spread tumors and early tumor of bowel segmental resections is used, which had a significantly higher risks of postoperative complications development. Hybrid laparoendoscopic surgery included a combination of laparoscopic and endoscopic technologies becomes a great opportunity to local bowel resection. This surgical procedure is accompanied by a minimal risk frequency of postoperative complications and the length of stay. In the two clinical cases we demonstrate techniques of hybrid laparoendoscopic surgery for “difficult” endoscopically unresectable polyps of the colon.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126458044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-15DOI: 10.17650/2782-3202-2023-3-1-48-52
B. G. Pkheshkhova, A. Mudunov, M. Pak, P. A. Zeynalova, A. Batsev
This article presents the experience of successful use of immunotherapy in treatment of locally advanced inoperable squamous cell carcinoma of the hairy part of the head.
本文介绍了免疫疗法在治疗局部晚期不能手术的头部多毛部分鳞状细胞癌中的成功应用经验。
{"title":"Experience of successful use of immunotherapy in treatment of locally advanced inoperable squamous cell carcinoma of the hairy part of the head","authors":"B. G. Pkheshkhova, A. Mudunov, M. Pak, P. A. Zeynalova, A. Batsev","doi":"10.17650/2782-3202-2023-3-1-48-52","DOIUrl":"https://doi.org/10.17650/2782-3202-2023-3-1-48-52","url":null,"abstract":"This article presents the experience of successful use of immunotherapy in treatment of locally advanced inoperable squamous cell carcinoma of the hairy part of the head.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"216 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122379915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-15DOI: 10.17650/2782-3202-2023-3-1-61-67
Yu. E. Ryabukhina, P. A. Zeynalova, F. М. Abbasbeyli, O. L. Timofeeva, T. Valiev, A. G. Zhukov, N. Kupryshina
Use of microinfusion elastomeric pumps for extended administration of antitumor drugs improves patients’ quality of life during prolonged cyclic treatment because of the absence of venous complications and infusion allergic reactions during administration of cytostatic agents and targeted drugs.
{"title":"Application of autonomous extended infusion therapy systems in treatment of patients with hemoblastoses. Experience of the Oncohematology Division of the Clinical Hospital “Lapino”","authors":"Yu. E. Ryabukhina, P. A. Zeynalova, F. М. Abbasbeyli, O. L. Timofeeva, T. Valiev, A. G. Zhukov, N. Kupryshina","doi":"10.17650/2782-3202-2023-3-1-61-67","DOIUrl":"https://doi.org/10.17650/2782-3202-2023-3-1-61-67","url":null,"abstract":"Use of microinfusion elastomeric pumps for extended administration of antitumor drugs improves patients’ quality of life during prolonged cyclic treatment because of the absence of venous complications and infusion allergic reactions during administration of cytostatic agents and targeted drugs.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"139 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131884689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-15DOI: 10.17650/2782-3202-2023-3-1-53-60
Yu. E. Ryabukhina, P. A. Zeynalova, O. L. Timofeeva, F. М. Abbasbeyli, G. Allakhverdieva, A. G. Zhukov, T. Valiev
Follicular lymphoma (FL) is the most common indolent form of lymphoma and characterized by recurrent course and heterogenous clinical signs. Selection of treatment program for patients with newly diagnosed or recurrent FL is based primarily on the size of the tumor. While use of rituximab-containing regimens led to increased progression-free survival, in some cases tumors are refractory to rituximab. Understanding of molecular mechanisms of FL pathogenesis and action of anti-CD20 monoclonal antibodies allowed to develop new drugs with several advantages compared to rituximab. According to the data of large randomized trials, use of glycoengineered monoclonal anti-CD20 type II antibody obinutuzumab in combination with chemotherapy in patients with FL has manageable toxicity profile and longer progression-free survival and event-free survival compared to use of rituximab.
{"title":"Use of obinutuzumab in therapy of patients with newly diagnosed follicular lymphoma. Experience of the Oncohematology Division of the Clinical Hospital “Lapino”","authors":"Yu. E. Ryabukhina, P. A. Zeynalova, O. L. Timofeeva, F. М. Abbasbeyli, G. Allakhverdieva, A. G. Zhukov, T. Valiev","doi":"10.17650/2782-3202-2023-3-1-53-60","DOIUrl":"https://doi.org/10.17650/2782-3202-2023-3-1-53-60","url":null,"abstract":"Follicular lymphoma (FL) is the most common indolent form of lymphoma and characterized by recurrent course and heterogenous clinical signs. Selection of treatment program for patients with newly diagnosed or recurrent FL is based primarily on the size of the tumor. While use of rituximab-containing regimens led to increased progression-free survival, in some cases tumors are refractory to rituximab. Understanding of molecular mechanisms of FL pathogenesis and action of anti-CD20 monoclonal antibodies allowed to develop new drugs with several advantages compared to rituximab. According to the data of large randomized trials, use of glycoengineered monoclonal anti-CD20 type II antibody obinutuzumab in combination with chemotherapy in patients with FL has manageable toxicity profile and longer progression-free survival and event-free survival compared to use of rituximab.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126008450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：